Traders Buy Large Volume of Call Options on Genmab A/S (NASDAQ:GMAB)

Genmab A/S Sponsored ADR (NASDAQ:GMAB) was the target of some unusual options trading on Wednesday. Investors bought 41,576 call options on the stock. This is an increase of approximately 3,570% compared to the typical volume of 1,133 call options.

Genmab A/S Stock Down 3.1%

GMAB opened at $34.55 on Friday. Genmab A/S has a twelve month low of $23.62 and a twelve month high of $35.90. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The business has a 50 day moving average price of $32.65 and a 200 day moving average price of $28.92. The firm has a market cap of $21.56 billion, a P/E ratio of 27.20, a price-to-earnings-growth ratio of 1.94 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. Research analysts forecast that Genmab A/S will post 1.21 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

A number of hedge funds have recently bought and sold shares of the company. WINTON GROUP Ltd grew its stake in shares of Genmab A/S by 158.9% in the second quarter. WINTON GROUP Ltd now owns 40,900 shares of the company’s stock worth $1,124,000 after acquiring an additional 25,100 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Genmab A/S by 36.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares during the last quarter. Diversify Wealth Management LLC acquired a new position in Genmab A/S during the 1st quarter valued at $1,216,000. SummitTX Capital L.P. bought a new stake in Genmab A/S in the 1st quarter valued at $2,263,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Genmab A/S in the 1st quarter valued at $1,198,000. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on GMAB shares. New Street Research set a $43.00 target price on shares of Genmab A/S in a research note on Wednesday, July 22nd. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Genmab A/S in a report on Monday, September 14th. TD Cowen raised shares of Genmab A/S from a “hold” rating to a “buy” rating and lifted their price objective for the company from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Finally, Guggenheim upped their price objective on shares of Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $39.50.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.